Fig. 1
From: Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review

Estimated median prevalence of NPAEs with anti-malarial prophylaxis (P), treatment (T) or combined prophylaxis and treatment (C) [5]
From: Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review
Estimated median prevalence of NPAEs with anti-malarial prophylaxis (P), treatment (T) or combined prophylaxis and treatment (C) [5]